XTX Topco’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

XTX Topco’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-93,391	Closed	-$2.19K	–	3401
2025 Q1	$2.19K	Buy	93,391 +78,582	+531%	+$13.4K	﹤0.01%	2321
2024 Q4	$2.38K	Buy	14,809 +4,635	+46%	+$912	﹤0.01%	2210
2024 Q3	$2.35K	Sell	10,174 -9,027	-47%	-$3.31K	﹤0.01%	1999
2024 Q2	$10.4K	Buy	19,201 +2,213	+13%	+$1.75K	﹤0.01%	1686
2024 Q1	$17.3K	Buy	16,988 +5,237	+45%	+$3.83K	﹤0.01%	1628
2023 Q4	$6.7K	Sell	11,751 -333	-3%	-$204	﹤0.01%	1463
2023 Q3	$12.6K	Buy	+12,084	New	+$16.4K	﹤0.01%	1413

XTX Topco's VIRX Position: Q2 2025 in Review

XTX Topco sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2025, closing a stake of 93,391 shares — an estimated $2.19K sold.

XTX Topco first reported a position in VIRX in Q3 2023 and held it in 7 quarters. The position peaked at $17.3K in Q1 2024. 0 funds tracked by Wall St. Rank hold VIRX as of Q2 2025.

XTX Topco reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
XTX Topco sold 93,391 Viracta Therapeutics, Inc. Common Stock shares in Q2 2025, an estimated $2.19K.
XTX Topco first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2023 and held it in 7 quarters.
XTX Topco's Viracta Therapeutics, Inc. Common Stock position peaked at $17.3K in Q1 2024.
0 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2025.

Based on XTX Topco's 13F filing for Q2 2025, filed 12 Aug 2025.